V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
NCT00378560
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
1021
Enrollment
INDUSTRY
Sponsor class
Conditions
HPV Infections
Interventions
BIOLOGICAL:
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
BIOLOGICAL:
Comparator: Placebo
Sponsor
Merck Sharp & Dohme LLC